Coronary Artery Disease in Patients Suffering From Schizophrenia
NCT ID: NCT02885792
Last Updated: 2017-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2015-09-30
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study is to investigate the progression of arteriosclerosis in patients with schizophrenia at different stages of the disease, and to offer and implement adequate treatment for these patients according to their somatic condition. This study will identify risk factors of somatic diseases in these patients, with specific focus on early diagnoses, prevention, intervention and treatment of arteriosclerosis in schizophrenic patients.
The investigation is about the possibility of detecting any differences between developing arteriosclerosis in schizophrenia patients versus the general population, and how common risk factors are contributing to this process. The results of this study should provide important modifications in the clinical guidelines for treatment of patients diagnosed with schizophrenia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Debuting and chronic schizophrenia
ILLNESS HISTORY:
* Existing psychiatric and somatic diagnosis and treatment
* Charlson co-morbidity
MEASURE OF SOCIAL CONDITIONS
\- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.
MEASURE OF PSYCHIATRIC CONDITION::
* Positive and Negative Syndrome Scale (PANSS)
* Clinical Global Impression Scale (CGI)
* Columbia Suicide Severity Rating Scale (C-SSRS)
* Beck Cognitive Insight Scale
* Birchwood Insight Scale
CARDIOVASCULAR MEASUREMENT:
CT Coronary angiography (CT-CAG)
* Echocardiography
* Heart rate variability (HRV)
* Pulmonary function test (PFT)
* Toe blood pressure (TBP)
* Blood test
* Body composition analysis
* CT scan of upper abdomen
* Cardiovascular magnetic resonance imaging (CMR)
* Adipose tissue biopsy
Illness history
Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
Measure of social conditions
A self-report questionnaire measuring social isolation, including relations to family and friends.
Measure of psychiatric condition
This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
Cardiovascular measurement
This procedure is used to detect early identification of cardiovascular disease progression.
Matched controls
CARDIOVASCULAR MEASUREMENT:
* CT Coronary angiography (CT-CAG)
* Echocardiography
* Heart rate variability (HRV)
* Pulmonary function test (PFT)
* Toe blood pressure (TBP)
* Blood test
* Body composition analysis
* CT scan of upper abdomen
* Cardiovascular magnetic resonance imaging (CMR)
* Adipose tissue biopsy
Cardiovascular measurement
This procedure is used to detect early identification of cardiovascular disease progression.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Illness history
Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
Measure of social conditions
A self-report questionnaire measuring social isolation, including relations to family and friends.
Measure of psychiatric condition
This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
Cardiovascular measurement
This procedure is used to detect early identification of cardiovascular disease progression.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed statement of consent
* Age \> 18
Exclusion Criteria
* Pregnancy and also breastfeeding women
* Participants with severe claustrophobia
* Participants with lack of ability to cooperate with the planned study program.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg Psychiatric Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jørgen Aagaard
Chief consultant, Professor, Dr.Med.Sci.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Svend E. Jensen, MD
Role: PRINCIPAL_INVESTIGATOR
Aalborg University Hospital, Psychiatric Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital, Psychiatric Hospital
Aalborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jørgen Aagaard, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Jorgensen LR, Hegtmann CL, Straszek SPV, Hoyer C, Polcwiartek C, Petersen LJ, Dalgaard MK, Jensen SE, Nielsen RE. Peripheral artery disease in patients with schizophrenia as compared to controls. BMC Cardiovasc Disord. 2023 Mar 8;23(1):126. doi: 10.1186/s12872-023-03143-9.
Trab T, Attar R, Jensen SE, Grontved S, Frokjaer JB, Polcwiartek C, Nielsen RE. Coronary artery calcium in patients with schizophrenia. BMC Psychiatry. 2021 Aug 23;21(1):422. doi: 10.1186/s12888-021-03412-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-20140047
Identifier Type: -
Identifier Source: org_study_id